Fig. 2 | Signal Transduction and Targeted Therapy

Fig. 2

From: Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial

Fig. 2

Cross-reactivity of neutralizing antibody responses against SARS-CoV-2 prototype strain and main VOCs, including Alpha, Beta, Delta and Omicron, elicited by heterologous NVSI-06-07 booster, compared with those elicited by homologous BBIBP-CorV booster. The live-virus neutralizing antibody titers were detected on day 14 post-boost. Serum samples of 192 (half boosted with homologous vaccination and the other half boosted with heterologous vaccination) participants with sequential enrollment numbers in ≥6-month boosting-interval group were tested. Both neutralizing antibody GMTs and the ratio of neutralizing GMTs between heterologous and homologous boosters are provided in the figure. Data are presented as GMT and 95% CI. ****P < 0.0001

Back to article page